AbbVie Targets Mylan In Latest Effort To Shield Norvir Patents
Law360, New York (June 17, 2013, 8:18 PM EDT) -- AbbVie Inc. on Friday accused Mylan Pharmaceuticals Inc. of violating three of its patents by attempting to market a generic version of the HIV drug Norvir, according to a suit filed in Delaware federal court.
In its most recent attempt to maintain a hold on the HIV treatment market, AbbVie claims that Mylan's abbreviated new drug application for generic ritonavir capsules infringes on patents covering Norvir's pharmaceutical composition and formulation.
The complaint states that Mylan's infringement of the AbbVie patents will cause "irreparable harm" and seeks a ruling that the patents are valid and enforceable, that Mylan's ANDA infringes on the patents, and...
Stay ahead of the curve
In the legal profession, information is the key to success. You have to know what’s happening with clients, competitors, practice areas, and industries. Law360 provides the intelligence you need to remain an expert and beat the competition.
Access to case data within articles (numbers, filings, courts, nature of suit, and more.)
Access to attached documents such as briefs, petitions, complaints, decisions, motions, etc.
Create custom alerts for specific article and case topics and so much more!